Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic board backs higher bid amid shareholder holdout
16 Oct 2025, 05:28BAVA.CONASDAQ Copenhagen

Bavarian Nordic's board of directors on Thursday reiterated its recommendation for shareholders to accept a takeover offer from a private equity consortium led by Nordic Capital and Permira.

Private equity raises Bavarian Nordic bid, faces shareholder test
15 Oct 2025, 15:59BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has raised its takeover bid for Danish vaccine maker Bavarian Nordic to 250 Danish Krone per share from 233 Danish Krone.

Nordic Capital, Permira clear final hurdle for Bavarian Nordic takeover
9 Oct 2025, 12:24BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has received the final regulatory approval needed for its proposed takeover of Danish vaccine maker Bavarian Nordic.

Bavarian Nordic's mpox vaccine shows strong results in children
7 Oct 2025, 14:59BAVA.CONASDAQ Copenhagen

Bavarian Nordic said Tuesday its mpox and smallpox vaccine produced a strong immune response and was well-tolerated in children aged 2 to 11 in a clinical study.

Bavarian Nordic posts strong results ahead of PE buyout
22 Aug 2025, 05:38BAVA.CONASDAQ Copenhagen

Danish vaccine maker Bavarian Nordic on Friday reported a 33% rise in first-half revenue, posting strong results as it prepares for a takeover by a private equity consortium.

Bavarian Nordic agrees to DKK 19 billion takeover offer
6 Aug 2025, 20:30BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has agreed to acquire Danish vaccine maker Bavarian Nordic in an all-cash deal valuing the company at approximately 19 billion Danish Krone.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic Announces Start of Randomized Phase 2 Study Comparing PROSTVAC® and Chemotherapy versus Chemotherapy28 Feb 2011
Total number of voting rights and share capital in Bavarian Nordic A/S30 Dec 2010
Bavarian Nordic awards warrants to certain employees16 Dec 2010
Bavarian Nordic Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Trial of PROSTVAC®8 Dec 2010
Bavarian Nordic A/S completes registration of share capital increase and upgrades its expectations to year-end cash preparedness6 Dec 2010
Bavarian Nordic A/S - Articles of Association6 Dec 2010
Bavarian Nordic A/S - Major Shareholder Announcement6 Dec 2010
Bavarian Nordic A/S launches a private placement at market price30 Nov 2010
Bavarian Nordic A/S completes a private placement at market price30 Nov 2010
Bavarian Nordic A/S - Interim Report for the period 1 January to 30 September 20109 Nov 2010
Bavarian Nordic Receives NIH Grant to Investigate the Potential of an MVA-BN® based Vaccine against Ebola and Marburg Viruses13 Oct 2010
US Government Exercises Next Part of Bavarian Nordic's Freeze-Dried IMVAMUNE® Contract12 Oct 2010
  • Previous
  • 1
  • More pages
  • 50
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 51
  • 52
  • More pages
  • 78
  • Next
  • Filings
    927